Merz gets European approval for Xeomin to treat chronic sialorrhea in adults

This article was originally published here

Xeomin is claimed to be the first and only neurotoxin with this approved indication in the EU. It secured approval from the US Food and Drug Administration (FDA)

The post Merz gets European approval for Xeomin to treat chronic sialorrhea in adults appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply